108results about "Proteoglycans" patented technology

The present invention provides a method of determining clostridial toxin activity by (a) contacting with a sample a cell containing a clostridial toxin substrate that includes a donor fluorophore; an acceptor having an absorbance spectrum overlapping the emission spectrum of the donor fluorophore; and a clostridial toxin recognition sequence containing a cleavage site that intervenes between the donor fluorophore and the acceptor, where resonance energy transfer is exhibited between the donor fluorophore and the acceptor under the appropriate conditions; (b) exciting the donor fluorophore; and (c) determining resonance energy transfer of the contacted cell relative to a control cell, where a difference in resonance energy transfer of the contacted cell as compared to the control cell is indicative of clostridial toxin activity.

The present invention provides the prophylaxis and treatment of bone and joint diseases by regulating the expression or activity of calmodulin, the prophylaxis and treatment of bone and joint diseases by regulating the expression or activity of asporin, and a diagnostic method for genetic susceptibility to bone and joint diseases by detecting polymorphisms in the CALM1 gene and / or the asporin gene, and the like.

The present invention provides for recombinant Endo-S mutants that exhibit reduced hydrolysis activity and increased transglycosylation activity for the synthesis of glycoproteins wherein a desired sialylated oxazoline or synthetic oligosaccharide oxazoline is added to a core fucosylated or nonfucosylated GlcNAc-protein acceptor. Such recombinant Endo-S mutants are useful for efficient glycosylation remodeling of IgGl-Fc domain to provide different antibody glycoforms carrying structurally well-defined Fc N-glycans.

Disclosed is a panel of biomarkers associated with angiogenesis, and the use of such biomarkers (genes, proteins, homologues and analogs thereof) to regulate angiogenesis. Methods for identifying compounds useful for regulating angiogenesis and conditions related thereto are disclosed.

Methods of stabilizing collagen fibrils in a cornea are disclosed. The stabilization may be effected by treating the cornea with a protein that crosslinks collagen fibrils, such as decorin. The stablization methods include treatment of corneas before, during, or after a surgical procedure, treatment of keratectasia, and treatment of keratoconus.

The present invention provides a peptide derived from the extracellular domain of syndecan-1 that inhibits angiogenesis.

This invention pertains to the field of hyaluronic acid-binding synthetic peptidoglycans and methods of forming and using the same.

Transgenically produced decorin and methods of making and using transgenically produced decorin.

Compositions and methods are provided for promoting elastin fiber formation (elastogenesis) in a cell, including methods that comprise contacting a cell that is capable of elastogenesis with (i) a mutated biglycan polypeptide that lacks chondroitin sulphate proteoglycan chains, (ii) a versican V3 isoform polypeptide that lacks most or all of the polypeptide regions encoded by one or more of exons 4, 5 or 6 or by exons 9-10 or 11-13, and / or with (iii) metastatin.

A transgenic mouse whose genome comprises a transcriptional control region operably linked to a cDNA encoding calreticulin (CRT) is described.

The present invention relates to the field of cellular immunotherapy for tumors and, more particularly, to a recombinant plasmid for the construction of recombinant malaria parasites and their use, wherein the recombinant plasmid is a tumorigenin-specific antigen gene inserted into the pL0017 plasmid, Recombinant malaria parasite, comprising the recombinant plasmid. Compared with plasmid DNA and RNA vector, the recombinant malaria parasite can be multiplied by the proliferation of Plasmodium, which is beneficial to the increase of the antigen in vivo. Compared with the defective virus and bacterial carrier, it survives in the red blood cells of the body longer, not short-term by the body's immune system to clear, long-term effective expression of exogenous tumor antigen, is conducive to long-term antigen and immune stimulation. The recombinant malaria parasite is capable of activating the high expression of Th1-related cytokines in vivo and increasing the proportion of CD8a + DCs in total CD11c + DCs and further activating specific cytotoxic T lymphocyte responses against tumor antigens, which is beneficial to the antitumor effect of the vaccine.

The invention relates to the field of biotechnology and gene treatment, and in particular to an oncolytic adenovirus, a carrier for preparing the same and an application thereof. The oncolytic adenovirus can coexpress decorin and GM-CSF proteins. The oncolytic adenovirus is applied to treating colon cancer, thereby providing an effectively immunogene treatment scheme for treatment of colon cancer.

The invention provides a hepatocellular carcinoma vaccine targeting secondary lymphoid tissues. The vaccine comprises fusion protein comprising (a) phosphatidylinositol proteoglycan-3 (GPC3) and (b) lymphocyte chemotactic factor (XCL1) polypeptide of a specifically bonded chemokine receptor 1 (XCR1), nucleic acid encoding the fusion protein and vectors of the nucleic acid, wherein (a) is connectedwith (b) through a linker, and (a) lacks amino acid residues with a cell membrane anchoring effect. The vaccine comprises the fusion protein, the nucleic acid and / or the vectors, and application of the fusion protein, the nucleic acid and / or the expression vectors in prevention and treatment of liver cancers is provided. The vaccine has the effect of intervention of generation and development ofliver cancers, and can be applied to intervention of high-risk population of liver cancer, and for example, the vaccine can be applied to intervention of the generation progress of hepatitis B-relatedpatients to liver cancers.

Lower eukaryote host cells in which the function of at least one endogenous gene encoding a chaperone protein, such as a Protein Disulphide Isomerase (PDI), has been reduced or eliminated and at least one mammalian homolog of the chaperone protein is expressed are described. In particular aspects, the host cells further include a deletion or disruption of one or more O-protein mannosyltransferase genes, and / or overexpression of an endogenous or exogenous Ca2+ ATPase. These host cells are useful for producing recombinant glycoproteins in large amounts and for producing recombinant glycoproteins that have reduced O-glycosylation.

The present invention provides a method that allows highly efficient and highly reliable evaluation of genomic stability of pluripotent stem cells, a method for removing pluripotent stem cells that have been identified as genomically unstable by the evaluation method from a culture of pluripotent stem cells to be evaluated, and a synthetic peptide that can be used for the methods. The methods provided by the present invention include preparing a culture of pluripotent stem cells of interest and analyzing an expression level of calreticulin for the pluripotent stem cells in the culture followed by identifying genomic stability or genomic instability of the stem cells on the basis of the expression level of calreticulin.

The present invention is drawn to methods of stimulating or enhancing angiogenesis in a patient comprising, administering to said patient a therapeutically effective amount of an endorepellin protein, wherein said endorepellin protein has an amino acid sequence of domain V of perlecan or fragments or derivatives, analogs thereof; and stimulating or enhancing generation of blood vessels. The present invention is drawn to compositions for enhancing angiogenesis.

It is an object of the present invention to identify a glypican-3-derived peptide which can bind to HLA-A2 and activate human killer T cells, so as to provide a means for carrying out an immunotherapy which is able to target approximately 40% of Japanese patients suffering from several types of cancers, which express GPC3 at a high level. The present invention provides a peptide of any of the following (A) or (B):(A) a peptide, which has the amino acid sequence as shown in any one of SEQ ID NOS: 1 to 3; or(B) a peptide, which has an amino acid sequence comprising a substitution or addition of one or two amino acids with respect to the amino acid sequence as shown in any one of SEQ ID NOS: 1 to 3, and which has ability to induce killer T cells.

Purified synthetic polypeptide ligands for targeting pharmaceutical agents and carriers comprising such agents to intestinal epithelial tissue, especially Peyer's patch and / or M-Cell tissue. Also methods of using the ligands.

The present application is directed to plants with improved properties where the expression of calreticulin, BET1-like polypeptides, DUS1-like polypeptides, ES43-like polypeptides, H0N5-like polypeptides or GSA1 polypeptides are modified. The improved property can be enhanced yield.

An efficient low-cost method of proteoglycan recovery from natural resources. There is provided a process for producing proteoglycan, comprising the steps of immersing a biological sample containing proteoglycan in an alkali solution of 0.0025 to 0.1 N and recovering the solution after the immersion. As compared with the conventional extraction method, proteoglycan can be recovered in unaltered undecomposed form easily within a short period of time, thereby attaining substantial reduction of proteoglycan production cost. Further, proteoglycan highly useful in industry can be recovered from wasted portions of fin, feather, mammal, etc. having mainly been discarded, thereby contributing toward effective utilization of industrial waste and reduction of the volume of industrial waste per se.

The present invention is directed to secreted and transmembrane polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.